Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Shire’s Lanadelumab Wows in Phase III Study

Shire’s 2015 bet on Dyax and its experimental drug to treat the rare illness, hereditary angioedema (HAE), is paying off. The company revealed stellar Phase III data for lanadelumab that could transform the way HAE patients are treated.

Read More »

European Approval for Label Extension of Cinryze

The European Commission approved a label extension for three new indications for Shire’s Cinryze, broadening its use to children with hereditary angioedema.

Read More »

Still Yearning for Baxalta, Shire Snaps Up Dyax in $5.9 Billion Deal

Dublin-based Shire (SHPG) announced today that it will acquire Burlington, Mass.-based Dyax Corporation (DYAX) for about $5.9 billion. Shire will pay $37.30 per Dyax share in cash, totaling around $5.9 billion. In addition, if Dyax’s pipeline product, DX-2930 for the treatment of HAE, a rare, debilitating genetic inflammatory condition, is approved, Dyax shareholders will receive […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom